Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Change in Account Payables (2016 - 2025)

Historic Change in Account Payables for Seres Therapeutics (MCRB) over the last 11 years, with Q3 2025 value amounting to -$515000.0.

  • Seres Therapeutics' Change in Account Payables fell 145526.32% to -$515000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$6.6 million, marking a year-over-year decrease of 7196.75%. This contributed to the annual value of -$2.9 million for FY2024, which is 7460.7% up from last year.
  • Latest data reveals that Seres Therapeutics reported Change in Account Payables of -$515000.0 as of Q3 2025, which was down 145526.32% from $79000.0 recorded in Q2 2025.
  • Seres Therapeutics' Change in Account Payables' 5-year high stood at $7.2 million during Q2 2022, with a 5-year trough of -$6.5 million in Q1 2022.
  • In the last 5 years, Seres Therapeutics' Change in Account Payables had a median value of $38000.0 in 2024 and averaged -$281842.1.
  • Its Change in Account Payables has fluctuated over the past 5 years, first surged by 90886.08% in 2022, then plummeted by 145526.32% in 2025.
  • Seres Therapeutics' Change in Account Payables (Quarter) stood at $4.6 million in 2021, then grew by 19.04% to $5.5 million in 2022, then crashed by 192.41% to -$5.0 million in 2023, then rose by 17.4% to -$4.2 million in 2024, then skyrocketed by 87.63% to -$515000.0 in 2025.
  • Its last three reported values are -$515000.0 in Q3 2025, $79000.0 for Q2 2025, and -$2.0 million during Q1 2025.